الفهرس 
Kidney and hypertensionOnly 14 pages are availabe for public view
 |  | from | 235 |  |  |
| | | from | 235 | | |
Abstract
The prevalence of chronic renal diseases is increasing worldwide. There is a great need to identify therapies that arrest disease progression to end-stage renal failure. Inhibition of the renin-angiotensin system both by ACEIs and ARBs is probably the best therapeutic option available. However, the number of patients who reach end-stage renal failure is still considerably high. Significant reduction of the incidence of ESRD is likely to be achieved in the near future for chronic nephropathies, provided that the degree of renoprotection can be improved. The present study was intended to study the potential renoprotective effect of ramipril, valsartan and rilmenidine on adenine induced nephropathy in rats. Also, to study the possible effect of combination of above mentioned drugs. The study included 125 male albino rats and were given excessive adenine diet (150mg) in 0.5 ml saline by gavage feeding once daily for 10 days. Rats that survive throughout the study will be divided into two main groups. Group I start treatment after 2 weeks of adenine administration and the Group II start treatment after 4 weeks of adenine administration. The results obtained were non-significant decrease of serum creatinine, endothelin and microalbuminuria in both groups I and group II with oral administration of rilmenidine. Oral administration of ramipril or valsartan produced significant reduction of creatinine, microalbuminuria in Group I; On the other hand, it produced non-significant change in serum creatinine level in Group II. Oral administration of rilmenidine or ramipril or valsartan produced significant increase of serum nitrate level when compared to positive control group I. Also, when compared to positive control group II. Oral administration of ramipril produced highly significant decrease of plasma endothelin levels when compared to positive control group I. On other hand, it produced non-significant decrease of plasma endothelin levels when comparing versus positive control group II. Oral administration of valsartan produced highly significant decrease of plasma endothelin levels when compared to positive control group I. Also, when compared to positive control group II. Oral administration of rilmenidine or ramipril or valsartan produced non-significant decrease of tubulointerstitial index when compared to positive control group I Also, when compared to positive control group II. There was highly significant decrease of serum creatinine, plasma endothelin levels and urinary microalbuminuria levels when comparing ramipril treated group in group-I versus ramipril treated group in group-II and also in valsartan treated group in group-I versus valsartan treated group in group-II.